Fig. 5

miR-330-5p targets and suppresses the expression of LDOC1. a Prediction of miR-330-5p downstream target genes; the 6 triangles represent the genes that were down-regulated in GSE63514, and the prediction results of target genes of miR-330-5p based on five different databases; the middle part represents the intersection of six sets of data. b Detection of LDOC1 expression in cancer tissues and adjacent tissues by RT-qPCR (N = 68, p < 0.05 vs. adjacent tissues). c Immunohistochemical detection of LDOC1 expression in cancer tissues and adjacent tissues (magnification: ×200, scale: 50 μm, N = 68, p < 0.05 vs. adjacent tissues). d correlation analysis of LDOC1 and miR-330-5p expression. N = 68. e Binding sites of miR-330-5p on LDOC1. f The binding of LDOC1 and miR-330-5p verified by dual luciferase reporter assay (*p < 0.05 vs. cells treated with mimic NC). g LDOC1 bound to Ago2 measured by RIP (*p < 0.05 vs. cells treated with anti-IgG). h LDOC1 protein expression in HeLa cells determined by Western blot analysis (*p < 0.05 vs. cells treated with oe-NC and NC mimic; ^#p < 0.05 vs. cells transfected with oe-HAND2-AS1 and NC mimic). The paired t test was used to measure the data of cancer tissues and adjacent tissues. The positive rate of immunohistochemistry in the two groups was tested by Chi square test, while one-way analysis of variance was used for comparison among multiple groups followed by Tukey’s post hoc test. The experiment was performed three times. LDOC1 leucine zipper down-regulated in cancer 1, IgG immunoglobulin G